Analysis Of Short-term Efficacy Of Sacubitril/Valsartan In Chronic Heart Failure

Background Heart failure(HF)is the end-stage manifestation of various cardiovascular diseases and the main cause of death,seriously harming the health of patients,reducing the quality of life,and ultimately affecting lifespan.In recent years,with the socio-economic development of our country and the improvement of people's living standards,the incidence of various cardiovascular diseases has increased day by day,so the number of patients with heart failure has also increased,which has brought very heavy pressure and pressure to patients,families and society.Burden is one of the two major challenges in the cardiovascular field in the 21 st century.The goal of treatment of heart failure is not only to significantly improve symptoms and improve quality of life,but also to delay or even prevent the further development of myocardial remodeling,thereby reducing the patient's rehospitalization rate and mortality.At the end of 2017,a new oral drug for the treatment of heart failure,angiotensin receptor-neprilysin inhibitors(ARNI)was launched in China,and its representative drug is sacubitril valsartan trade name: Nuo xin tuo,has the dual functions of inhibiting the renin-angiotensin-aldosterone system and enkephalinase,diuretic,hypotensive,reversing myocardial remodeling and other beneficial effects.At present,the drug has few clinical studies in China.In this study,we retrospectively analyzed 60 cases of chronic heart failure and compared the therapeutic effects of ARNI(Sacubitril Valsartan)and ACEI drugs(Perindopril)on patients with chronic heart failure.Extensive clinical treatment provides clinical evidence.Objective By comparing the clinical effects of sacubitril valsartan and perindopril in the treatment of patients with chronic heart failure within 3 months,mainly including NYHA cardiac function grading and 6-minute walk test(6-MWT)?Rehospitalization rate and mortality rate;changes in cardiac function color Doppler ultrasound indexes(LVEDD,LVEF),changes in N-terminal pro-brain natriuretic peptide(NT-pro BNP)and adverse reactions(Hypotension,cough,and impaired renal function),with a view to obtaining the effect of sacubatril valsartan on chronic heart failure is better than perindopril,and the adverse reactions are not higher than perindopril.Method A total of 60 patients with chronic heart failure who were admitted to the Department of Cardiology of the Fifth Hospital of Guangzhou Medical University from February 2018 to August 2019 were collected.The other medications were basically the same(diuretics,spironolactone,beta receptor antagonists).It was divided into an observation group(referred to as group A,sacubatril valsartan)and a control group(referred to as group B,perindopril).The clinical effects(NYHA heart function changes,NYHA heart function,6-MWT and rehospitalization rate,mortality),changes in cardiac function color Doppler ultrasound indexes(LVEDD,LVEF),changes in N-terminal pro-brain natriuretic peptide(NT-pro BNP)and adverse effects reaction.Result 1.There was no statistical difference in the basic data(gender,age,smoking history,history of hyperlipidemia,history of hypertension,history of diabetes,and other medications)between the two groups(P >0.05).2.Compared with before and after treatment in the same group,the overall effective rates of NYHA cardiac function improvement in the two groups A and B were 93.33% and 86.67% respectively;the 6-MWT and LVEF increased in the two groups,and P <0.05,all with statistical differences;NT-pro BNP and LVEDD decreased in both groups,P<0.05,both of which were statistically different.3.Compared with before and after treatment in the between group,the clinical effect(NYHA cardiac function grade)of ARNI group and ACEI group had a difference in effectiveness,but there was no statistical difference(P = 0.3834,>0.05);the re-admission rate after treatment between the two groups They were 26.7% in group A and 36.7% in group B,and there was no statistical difference between the groups(P = 0.4051,>0.05);the post-treatment mortality rates between the two groups were 6.7% in group A and 10% in group B,and no statistics between groups The academic difference(P = 0.6404,>0.05);the ARNI group's cardiac function indicators(LVEF,LVEDD,NT-pro BNP)improved more significantly,and there was a statistical difference,all P<0.05.Conclusion Both Sacubitril/Valsartan and Perindopril improved cardiac function in patients with chronic heart failure after 3 months of treatment.Compared with Perindopril,Sacubatril/ Valsartan is better than perindopril in treating chronic heart failure.There was no significant difference in the occurrence of adverse reactions.